Hemispherx Biopharma Inc. changed its name to AIM ImmunoTech Inc. and its shares will trade under the ticker AIM on the NYSE American, effective Sept. 3.
The Ocala, Fla.-based company has rebranded to reflect its increasing focus on developing immunological agents to treat multiple types of cancer and severe immune-deficiency diseases such as chronic fatigue syndrome.
The company is carrying out various clinical studies on its flagship product rintatolimod, marketed as Ampligen or Rintamod, as a treatment for cancer. The drug is approved in Argentina to treat patients with myalgic encephalomyelitis, or chronic fatigue syndrome, since 2016.
The drug was also awarded orphan-drug status by the U.S. Food and Drug Administration for the same indication.
The NYSE American targets growing companies.
